A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia.
<h4>Background</h4>Although accumulating evidence suggests a more extensive reduction of low-density lipoprotein cholesterol (LDL-C), it is unclear whether a higher statin dose is more effective and cost-effective in the Asian population. This study compared the efficacy, safety, and cos...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0245481 |
id |
doaj-f0a93cd523294e3a89df697e8c8272e0 |
---|---|
record_format |
Article |
spelling |
doaj-f0a93cd523294e3a89df697e8c8272e02021-03-25T05:32:19ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01161e024548110.1371/journal.pone.0245481A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia.Ji Bak KimWoo Hyuk SongJong Sung ParkTae-Jin YounYong Hyun ParkShin-Jae KimSung Gyun AhnJoon-Hyung DohYun-Hyeong ChoJin Won Kim<h4>Background</h4>Although accumulating evidence suggests a more extensive reduction of low-density lipoprotein cholesterol (LDL-C), it is unclear whether a higher statin dose is more effective and cost-effective in the Asian population. This study compared the efficacy, safety, and cost-effectiveness of atorvastatin 20 and 10 mg in high-risk Asian patients with hypercholesterolemia.<h4>Methods</h4>A 12-week, open-label, parallel, multicenter, Phase IV randomized controlled trial was conducted at ten hospitals in the Republic of Korea between October 2017 and May 2019. High-risk patients with hypercholesterolemia, defined according to 2015 Korean guidelines for dyslipidemia management, were eligible to participate. We randomly assigned 250 patients at risk of atherosclerotic cardiovascular disease to receive 20 mg (n = 124) or 10 mg (n = 126) of atorvastatin. The primary endpoint was the difference in the mean percentage change in LDL-C levels from baseline after 12 weeks. Cost-effectiveness was measured as an exploratory endpoint.<h4>Results</h4>LDL-C levels were reduced more significantly by atorvastatin 20 mg than by 10 mg after 12 weeks (42.4% vs. 33.5%, p < 0.0001). Significantly more patients achieved target LDL-C levels (<100 mg/dL for high-risk patients, <70 mg/dL for very high-risk patients) with atorvastatin 20 mg than with 10 mg (40.3% vs. 25.6%, p < 0.05). Apolipoprotein B decreased significantly with atorvastatin 20mg versus 10 mg (-36.2% vs. -29.9%, p < 0.05). Lipid ratios also showed greater improvement with atorvastatin 20 mg than with 10 mg (total cholesterol/high-density lipoprotein cholesterol ratio, -33.3% vs. -29.4%, p < 0.05; apolipoprotein B/apolipoprotein A1 ratio, -36.7% vs. -31.4%, p < 0.05). Atorvastatin 20 mg was more cost-effective than atorvastatin 10 mg in terms of both the average and incremental cost-effectiveness ratios. Safety and tolerability of atorvastatin 20 mg were comparable to those of atorvastatin 10 mg.<h4>Conclusion</h4>In high-risk Asian patients with hypercholesterolemia, atorvastatin 20 mg was both efficacious in reducing LDL-C and cost-effective compared with atorvastatin 10 mg.https://doi.org/10.1371/journal.pone.0245481 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ji Bak Kim Woo Hyuk Song Jong Sung Park Tae-Jin Youn Yong Hyun Park Shin-Jae Kim Sung Gyun Ahn Joon-Hyung Doh Yun-Hyeong Cho Jin Won Kim |
spellingShingle |
Ji Bak Kim Woo Hyuk Song Jong Sung Park Tae-Jin Youn Yong Hyun Park Shin-Jae Kim Sung Gyun Ahn Joon-Hyung Doh Yun-Hyeong Cho Jin Won Kim A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia. PLoS ONE |
author_facet |
Ji Bak Kim Woo Hyuk Song Jong Sung Park Tae-Jin Youn Yong Hyun Park Shin-Jae Kim Sung Gyun Ahn Joon-Hyung Doh Yun-Hyeong Cho Jin Won Kim |
author_sort |
Ji Bak Kim |
title |
A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia. |
title_short |
A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia. |
title_full |
A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia. |
title_fullStr |
A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia. |
title_full_unstemmed |
A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia. |
title_sort |
randomized, open-label, parallel, multi-center phase iv study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk asian patients with hypercholesterolemia. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2021-01-01 |
description |
<h4>Background</h4>Although accumulating evidence suggests a more extensive reduction of low-density lipoprotein cholesterol (LDL-C), it is unclear whether a higher statin dose is more effective and cost-effective in the Asian population. This study compared the efficacy, safety, and cost-effectiveness of atorvastatin 20 and 10 mg in high-risk Asian patients with hypercholesterolemia.<h4>Methods</h4>A 12-week, open-label, parallel, multicenter, Phase IV randomized controlled trial was conducted at ten hospitals in the Republic of Korea between October 2017 and May 2019. High-risk patients with hypercholesterolemia, defined according to 2015 Korean guidelines for dyslipidemia management, were eligible to participate. We randomly assigned 250 patients at risk of atherosclerotic cardiovascular disease to receive 20 mg (n = 124) or 10 mg (n = 126) of atorvastatin. The primary endpoint was the difference in the mean percentage change in LDL-C levels from baseline after 12 weeks. Cost-effectiveness was measured as an exploratory endpoint.<h4>Results</h4>LDL-C levels were reduced more significantly by atorvastatin 20 mg than by 10 mg after 12 weeks (42.4% vs. 33.5%, p < 0.0001). Significantly more patients achieved target LDL-C levels (<100 mg/dL for high-risk patients, <70 mg/dL for very high-risk patients) with atorvastatin 20 mg than with 10 mg (40.3% vs. 25.6%, p < 0.05). Apolipoprotein B decreased significantly with atorvastatin 20mg versus 10 mg (-36.2% vs. -29.9%, p < 0.05). Lipid ratios also showed greater improvement with atorvastatin 20 mg than with 10 mg (total cholesterol/high-density lipoprotein cholesterol ratio, -33.3% vs. -29.4%, p < 0.05; apolipoprotein B/apolipoprotein A1 ratio, -36.7% vs. -31.4%, p < 0.05). Atorvastatin 20 mg was more cost-effective than atorvastatin 10 mg in terms of both the average and incremental cost-effectiveness ratios. Safety and tolerability of atorvastatin 20 mg were comparable to those of atorvastatin 10 mg.<h4>Conclusion</h4>In high-risk Asian patients with hypercholesterolemia, atorvastatin 20 mg was both efficacious in reducing LDL-C and cost-effective compared with atorvastatin 10 mg. |
url |
https://doi.org/10.1371/journal.pone.0245481 |
work_keys_str_mv |
AT jibakkim arandomizedopenlabelparallelmulticenterphaseivstudytocomparetheefficacyandsafetyofatorvastatin10and20mginhighriskasianpatientswithhypercholesterolemia AT woohyuksong arandomizedopenlabelparallelmulticenterphaseivstudytocomparetheefficacyandsafetyofatorvastatin10and20mginhighriskasianpatientswithhypercholesterolemia AT jongsungpark arandomizedopenlabelparallelmulticenterphaseivstudytocomparetheefficacyandsafetyofatorvastatin10and20mginhighriskasianpatientswithhypercholesterolemia AT taejinyoun arandomizedopenlabelparallelmulticenterphaseivstudytocomparetheefficacyandsafetyofatorvastatin10and20mginhighriskasianpatientswithhypercholesterolemia AT yonghyunpark arandomizedopenlabelparallelmulticenterphaseivstudytocomparetheefficacyandsafetyofatorvastatin10and20mginhighriskasianpatientswithhypercholesterolemia AT shinjaekim arandomizedopenlabelparallelmulticenterphaseivstudytocomparetheefficacyandsafetyofatorvastatin10and20mginhighriskasianpatientswithhypercholesterolemia AT sunggyunahn arandomizedopenlabelparallelmulticenterphaseivstudytocomparetheefficacyandsafetyofatorvastatin10and20mginhighriskasianpatientswithhypercholesterolemia AT joonhyungdoh arandomizedopenlabelparallelmulticenterphaseivstudytocomparetheefficacyandsafetyofatorvastatin10and20mginhighriskasianpatientswithhypercholesterolemia AT yunhyeongcho arandomizedopenlabelparallelmulticenterphaseivstudytocomparetheefficacyandsafetyofatorvastatin10and20mginhighriskasianpatientswithhypercholesterolemia AT jinwonkim arandomizedopenlabelparallelmulticenterphaseivstudytocomparetheefficacyandsafetyofatorvastatin10and20mginhighriskasianpatientswithhypercholesterolemia AT jibakkim randomizedopenlabelparallelmulticenterphaseivstudytocomparetheefficacyandsafetyofatorvastatin10and20mginhighriskasianpatientswithhypercholesterolemia AT woohyuksong randomizedopenlabelparallelmulticenterphaseivstudytocomparetheefficacyandsafetyofatorvastatin10and20mginhighriskasianpatientswithhypercholesterolemia AT jongsungpark randomizedopenlabelparallelmulticenterphaseivstudytocomparetheefficacyandsafetyofatorvastatin10and20mginhighriskasianpatientswithhypercholesterolemia AT taejinyoun randomizedopenlabelparallelmulticenterphaseivstudytocomparetheefficacyandsafetyofatorvastatin10and20mginhighriskasianpatientswithhypercholesterolemia AT yonghyunpark randomizedopenlabelparallelmulticenterphaseivstudytocomparetheefficacyandsafetyofatorvastatin10and20mginhighriskasianpatientswithhypercholesterolemia AT shinjaekim randomizedopenlabelparallelmulticenterphaseivstudytocomparetheefficacyandsafetyofatorvastatin10and20mginhighriskasianpatientswithhypercholesterolemia AT sunggyunahn randomizedopenlabelparallelmulticenterphaseivstudytocomparetheefficacyandsafetyofatorvastatin10and20mginhighriskasianpatientswithhypercholesterolemia AT joonhyungdoh randomizedopenlabelparallelmulticenterphaseivstudytocomparetheefficacyandsafetyofatorvastatin10and20mginhighriskasianpatientswithhypercholesterolemia AT yunhyeongcho randomizedopenlabelparallelmulticenterphaseivstudytocomparetheefficacyandsafetyofatorvastatin10and20mginhighriskasianpatientswithhypercholesterolemia AT jinwonkim randomizedopenlabelparallelmulticenterphaseivstudytocomparetheefficacyandsafetyofatorvastatin10and20mginhighriskasianpatientswithhypercholesterolemia |
_version_ |
1714766399622086656 |